Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Research Bridge Partners is a venture capital firm that specializes in formative investments in biomedical startups. Founded by Isaac Barchas and Reid Hoffman, the firm operates out of the United States. The organization aims to bridge the gap between research universities located in the mid-continent and commercialization centers such as the Bay Area and Boston. This focus allows them to target high-quality investment opportunities that are often overlooked due to limited commercialization resources.
The firm employs both tax-exempt and for-profit capital to support early-stage startups, optimizing the societal benefits of scientific research. Research Bridge Partners is committed to enhancing the commercialization of academic breakthroughs, thereby contributing to advancements in the biotech and healthcare sectors.
Research Bridge Partners invests primarily in biomedical startups that emerge from breakthroughs at leading mid-continent universities. Their investment strategy is centered on utilizing proprietary analytics to identify promising academic researchers. The firm collaborates closely with these researchers to establish the necessary protections and infrastructure that are crucial for startup success.
Engaging in seed-stage investments, Research Bridge Partners develops tailored capitalization strategies that align with the specific intellectual property and market conditions of each startup. This approach ensures that they can effectively support the commercialization of innovative biomedical solutions.
Lydia McClure - CEO and Board Chair, brings extensive leadership experience in the biotech sector.
Ann Arvin - Director, Senior Vice President of Vir Biotechnology, has a strong background in biotech investments.
Lydia Meyer-Turkson - Director, formerly Head of Public Private Partnerships at Phillips, specializes in strategic partnerships.
Matt Tremblay - Director and CEO of Blackbird Laboratories, has a proven track record in startup leadership.
Isaac Barchas - Special Advisor and Director, co-founder with significant experience in venture capital.
Sunil Singhal - Venture Partner, brings expertise in healthcare investments.
William Maul Measey - Professor in Surgical Research at UPenn Medicine, provides academic insights.
Jim Graham - Managing Director of Investments, oversees investment strategies.
Ryan Field - Advisor, offers strategic guidance.
Maggie Colonnetta - Senior Associate, supports investment analysis.
Andrew Cox - Senior Associate, involved in deal sourcing.
Gil Cloyd - CTO at Procter & Gamble (former), Founding Board Member, brings corporate experience.
Linda Grais - CEO of Ocera Therapeutics (former), Founding Board Member, has extensive industry knowledge.
Reid Hoffman - Partner at Greylock Partners, Founding Board Member, known for his influence in the venture capital space.
To pitch Research Bridge Partners, founders should reach out through the firm's website. A well-prepared pitch deck should include details about the scientific breakthrough, market analysis, and the team’s qualifications. There are no specific application forms mentioned, and response times may vary.
What are the investment criteria for Research Bridge Partners?
Research Bridge Partners focuses on seed-stage investments in biomedical startups that are based on breakthroughs from leading researchers at mid-continent universities. They look for high-quality opportunities that may be overlooked due to limited commercialization resources.
How can founders apply or pitch to Research Bridge Partners?
Founders interested in pitching to Research Bridge Partners should prepare a detailed presentation that outlines their startup's unique value proposition, the scientific breakthrough it is based on, and the market potential. Specific application forms or portals are not mentioned, so direct contact through their website is recommended.
What makes Research Bridge Partners different from other venture capital firms?
The firm distinguishes itself by focusing on the intersection of academic research and commercialization, specifically targeting breakthroughs from mid-continent universities. Their use of proprietary analytics to identify promising researchers is a key differentiator.
What is the geographic scope of Research Bridge Partners?
Research Bridge Partners primarily invests in the United States, with a specific focus on the mid-continent region and its connection to major commercialization hubs like the Bay Area and Boston.
What kind of post-investment involvement does Research Bridge Partners have?
While specific details on post-investment involvement are not provided, the firm collaborates closely with academic researchers to establish necessary protections and infrastructure, indicating a hands-on approach to supporting their portfolio companies.
What is the typical check size for investments made by Research Bridge Partners?
The firm specializes in seed-stage investments, but specific check sizes are not disclosed in the available information.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.